Of all the types of breast cancer, triple negative breast cancer (TNBC) is the most aggressive and lacks specific therapies.
Study Results Support the use of TellDx to Personalize Cancer Care Management –-- Clinical study published in Cancer Discovery --ANDOVER, ...
Cancer is a complex disease that evades the immune system through various mechanisms. The rapid proliferation of cells and their ability to resist therapy make cancer extremely aggressive. Solid ...
Marker Therapeutics (MRKR) is a clinical-stage immuno-oncology Company with the worldwide exclusive license of Multi-Antigen Targeted T cells, a ...
News-Medical.Net on MSN
DLL3 on circulating tumor cells predicts tarlatamab success in lung cancer
A team led by investigators at the Mass General Brigham Cancer Institute has discovered that a particular marker on tumor ...
Clinical study from Baylor College of Medicine demonstrates a favorable safety profile and up to 84.6% disease control rate in patients with ...
Marker Therapeutics, Inc. has announced a collaboration with Cellipont Bioservices to support the cGMP manufacturing of MT-601, its lead Multi-Antigen Recognizing (MAR)-T cell therapy, currently in ...
Hosted on MSN
Scientists identify markers of key stem cell populations driving colorectal cancer formation
Researchers from A*STAR Institute of Molecular and Cell Biology (A*STAR IMCB) have identified markers of two critical stem cell populations that drive colorectal cancer formation. Subscribe to our ...
CellVoyant, an AI-first biotech based in Bristol UK, today launches FateView™, the first online predictive cell analytics platform designed to help cell-based therapeutic drug developers reduce costs ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback